Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Business Journal.
Press releases published on July 1, 2025

Robinhood Markets, Inc. to Announce Second Quarter 2025 Results on July 30, 2025
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Today, Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) announced that it will release its second quarter 2025 financial results on Wednesday, July 30, 2025, after market close. Robinhood will host …

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. …

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an …

Eos Energy Announces Second Funding Under Its Department of Energy Loan Guarantee to Fuel U.S. Battery Manufacturing Capacity Expansion
TURTLE CREEK, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy …

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and …

Nasdaq Announces the Board of Directors of its U.S. Exchanges
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today announced the election of all nominated directors to the boards of the U.S. exchanges operated by the company, which include The Nasdaq Stock Market LLC, Nasdaq PHLX LLC, Nasdaq …

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it …

Phillips Edison & Company Inc. Invites You to Join Its Second Quarter 2025 Earnings Conference Call
CINCINNATI, July 01, 2025 (GLOBE NEWSWIRE) -- Phillips Edison …

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted …

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction
TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on June 30, 2025, the Company exchanged $6.5 million of its subordinated …

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an …

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including …

Bank OZK Announces Increase to Quarterly Common Stock Dividend and Announces Preferred Stock Dividend
LITTLE ROCK, Ark., July 01, 2025 (GLOBE NEWSWIRE) -- Bank OZK (the “Bank”) (Nasdaq: OZK) announced its Board of Directors declared a quarterly cash dividend on the Bank’s common stock of $0.44 per share, up $0.01, or 2.33% from the prior quarter. The …

DDD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that 3D Systems Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

VSTS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Vestis Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

WST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

CIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Civitas Resources, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

AAPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apple Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean- …